Related Experiment Video
Updated: Jun 27, 2026
Hydrogel Arrays Enable Increased Throughput for Screening Effects of Matrix Components and Therapeutics in 3D Tumor Models
Published on: June 16, 2022
Translating a Preclinical Hydrogel Platform into a Human Therapeutic for Delivering Targeted Low-Dose Anti-CTLA-4
1Division of Pulmonary & Critical Care, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1690, USA.
Abstract:
Systemic administration of antibodies that target immune checkpoint inhibitor pathways is a highly effective approach to cancer immunotherapy, but systemic toxicity can limit clinical utility. In preclinical testing, a peri-tumor injection of a low dose of hydrogel-encapsulated cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody was shown to selectively activate T cells in tumor-draining lymph nodes, induce tumor infiltration by cytotoxic T cells, and result in tumor regression, protective immunity, and long-term survival. In contrast to systemic therapy, there was limited systemic exposure or risk for autoimmune toxicity. The current study focuses on translating this platform into a biocompatible human therapeutic. The hydrogel matrix was reformulated using a low-molecular-weight hyaluronic acid. A recombinant human hyaluronidase (rHuPH20) was incorporated to promote lymph node targeting and self-resorbing features. Formulations were optimized to operate at neutral pH and with gelation kinetics allowing a 5 to 10 min administration window. Performance features were assessed including the capacity to encapsulate human IgG or ipilimumab antibody at proposed therapeutic doses (1-15 mg/mL), impact of rHuPH20 and antibody on rheologic properties and three-dimensional microstructure, and payload delivery profiles in vitro and in vivo. Results confirm the capacity for this unique hydrogel platform to be adapted for human testing.
Insights
This study developed a novel hydrogel platform for localized cancer immunotherapy using cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibodies. This approach minimizes systemic toxicity while enhancing anti-tumor immune responses for potential human therapeutic applications.
Area of Science:
- Oncology
- Immunology
- Biomaterials Science
Background:
- Systemic immune checkpoint inhibitor therapy, like cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibodies, shows efficacy in cancer treatment but is limited by systemic toxicity.
- Preclinical studies demonstrated that peri-tumoral injection of hydrogel-encapsulated CTLA-4 antibodies selectively activates T cells in tumor-draining lymph nodes, leading to tumor regression and protective immunity with reduced systemic exposure.
Purpose of the Study:
- To translate the preclinical hydrogel-encapsulated CTLA-4 antibody platform into a biocompatible human therapeutic.
- To optimize hydrogel formulation, incorporating hyaluronic acid and recombinant human hyaluronidase (rHuPH20), for enhanced lymph node targeting and self-resorption.
Main Methods:
- Reformulated the hydrogel matrix using low-molecular-weight hyaluronic acid and incorporated rHuPH20.
- Optimized formulations for neutral pH and a 5-10 minute administration window.
- Assessed hydrogel capacity to encapsulate human IgG or ipilimumab (1-15 mg/mL), the impact of rHuPH20 and antibody on rheology and microstructure, and in vitro/in vivo payload delivery.
Main Results:
- The hydrogel platform demonstrated successful encapsulation of human IgG and ipilimumab at therapeutic doses.
- Incorporation of rHuPH20 and antibodies showed manageable effects on rheologic properties and microstructure.
- In vitro and in vivo studies confirmed controlled payload delivery profiles.
Conclusions:
- The developed hydrogel platform is adaptable for human therapeutic use in localized cancer immunotherapy.
- This approach offers a promising strategy to enhance anti-tumor immunity while mitigating systemic autoimmune toxicity associated with CTLA-4 blockade.
